UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF THE
SECURITIES EXCHANGE ACT OF 1934
For the month of October 2026
Commission File Number 001-42468
CELLYAN
BIOTECHNOLOGY CO., LTD
(Translation of registrant’s name into English)
Room
B1, 5/F., Well Town Industrial Building,
13 Ko Fai Road, Yau Tong, Kowloon
Hong Kong
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
Cellyan Biotechnology Co., Ltd, a Cayman Islands company (the “Company”), furnishes under the cover of Form 6-K the following.
The information contained in this Report on Form 6-K, including Exhibit 99.1 hereto, is hereby incorporated by reference into the Company’s registration statement on Form F-3 (File No. 333-296754) and S-8 (Registration No. 333-298301).
1
EXHIBIT INDEX
| Exhibit No. | Description | |
| 99.1 | Press release - Cellyan Biotechnology Announces a 1-for-20 Reverse Stock Split |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Date: October 21, 2026 | CELLYAN BIOTECHNOLOGY CO., LTD | |
| By: | /s/ Chenyu Liang | |
| Chenyu Liang | ||
| Director and Chief Executive Officer | ||
3